Clinical Trial Update: Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial update for a tetravalent dengue vaccine (ChimeriVax) in healthy subjects; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Disease
• Dengue Fever
• Dengue Hemorrhagic Fever
• Dengue Virus Infection

Drugs mentioned

• ChimeriVax Tetravalent Dengue Vaccine (Chimerivax Tetravalent Dengue Vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Dengue Virus, Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-07-24